



Analysis of Large Clinical Trial Database Shows Atorvastatin (Lipitor) to be Well Tolerated by the Asian Population

Tokyo, October 25, 2012 - Astellas Pharma Inc. (Tokyo:4503; President and CEO: Yoshihiko Hatanaka) and Pfizer Japan Inc. (Headquarters: Tokyo; President: Ichiro Umeda) announced today that a large-scale retrospective database analysis on atorvastatin (Lipitor) has demonstrated that atorvastatin is as well tolerated by the Asian population as it is by the overall study population at all approved doses. The data were released at the 23rd Great Wall International Congress of Cardiology in Beijing.

In this retrospective analysis, 77,949 patients (including 3,191 Asian patients) in 58 atorvastatin clinical trials were included. Of these, 2,519 Asian patients received atorvastatin treatment. Out of the 58 clinical trials, the outcomes of the six long-term trials (median duration from 3.1 to 4.9 years) were analyzed individually and the 52 short-term trials (median duration from 4 to 72 weeks) that had included atorvastatin at doses ranging from 10 mg to 80 mg were pooled and analyzed by category. Furthermore, a separate analysis was performed on five trials that had been carried out in several countries and a region in Asia (China, South Korea, Taiwan, Thailand and the Philippines) that had enrolled Asian subjects only.

The analysis did not find any evidence indicating increased rates of adverse events in the Asian population compared with rates in the overall patient population. The rates of adverse events, serious adverse events, and discontinuations due to adverse events were similar for the Asian population and the overall patient population. Also, a dose-response relationship in adverse events was not found for the Asian population. The most frequently reported adverse event in the Asian population and the non-Asian population was gastrointestinal dysfunction. Among patients treated with atorvastatin, the incidence of adverse effects in the muscular system was lower in the Asian population than in the overall patient population, the incidence of myalgia being 8.0% among non-Asian patients and 6.7% among Asian patients. Among Asian patients, treatment-related serious adverse events were extremely rare, and no occurrence of rhabdomyolysis was found. For patients treated with atorvastatin, rates of elevations in liver enzymes for Asian patients were similar for the Asian population and the overall patient population.

Asia is facing a heart-health crisis, with heart disease, heart attack and stroke being major causes of death. In Southeast Asia, for example, an estimated 3.6 million deaths are due to cardiovascular diseases. In fact, people in the region die from cardiovascular diseases at relatively young ages, with 27% of all deaths due to cardiovascular diseases occurring before the age of 60 years,

compared to 16% in the rest of the world.¹ In a region where changing demographics and lifestyle drive an increasing incidence of cardiovascular diseases,¹⁻⁴ concerns about tolerability may mean that treatment is not optimized to achieve the goals set out by international guidelines,⁵ leaving many Asians at unnecessary risk of cardiovascular events.

Even though the benefit and safety profile of atorvastatin has been satisfactorily established through many international clinical trials and clinical experience spanning over 20 years, the safety data on Asian people (compared to those on non-Asians) have thus far been limited in scope.⁶⁻¹⁴

This analysis was the first large-scale database analysis performed to investigate the tolerability of atorvastatin at all approved doses in the overall subject population and in Asians in particular.

###

**The term “Asian population” used here refers to Asians, Orientals, South Asians, Indians, and Pacific Islanders. Japanese people were not included in the Asian population in this analysis.*

Contacts for inquiries or additional information	
Astellas Pharma Inc. Corporate Communications TEL:03-3244-3201 www.astellas.com/jp	Pfizer Japan Inc. Established Products Business Unit Communications TEL:03-5309-6719 www.pfizer.co.jp

References:

1. Department of Sustainable Development and Healthy Environment, World Health Organization. Cardiovascular Diseases fact sheet. September 2011. Available at: http://www.searo.who.int/linkfiles/non_communicable_diseases_cvd-fs.pdf. Accessed 25 September 2012
2. Ueshima H, et al. Circulation. 2008;118:2702-2709.
3. Peng X. Science. 2011;333:581-587
4. Hong Y. Clin Chem 2009;55:1450-1452.
5. Grundy SM, et al. Circulation 2004;110:227-239.
6. Sever PS, et al. Lancet 2003;361:1149-1158.
7. Cannon CP, et al. N Engl J Med 2004;350:1495-1504.
8. Colhoun HM, et al. Lancet 2004;364:685-696.
9. Koren MJ, et al. J Am Coll Cardiol 2004;44:1772-1779.
10. Pedersen TR, et al. JAMA 2005;294:2437-2445.
LaRosa JC, et al. N Engl J Med 2005;352:1425-1435.
11. Amarenco P, et al. N Engl J Med 2006;355:549-559.
12. Scandinavian Simvastatin Survival Study Group. Lancet 1994;344:1383-1389.
13. Heart Protection Study Collaborative Group. Lancet 2002;360:7-22.
14. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. National Cholesterol Education Program. National Heart, Lung, and Blood Institute National Institutes of Health, NIH Publication No. 02-5215 September 2002. Available at: www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf. Accessed 28 September 2012.